|
|
| | 3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester Basic information |
| Product Name: | 3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester | | Synonyms: | 3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester;Dovitinib-RIBOTAC | | CAS: | 2759351-68-1 | | MF: | C51H56FN9O10S | | MW: | 1006.11 | | EINECS: | | | Product Categories: | | | Mol File: | 2759351-68-1.mol | ![3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester Structure](CAS/20210305/GIF/2759351-68-1.gif) |
| | 3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester Chemical Properties |
| density | 1.395±0.06 g/cm3(Predicted) | | pka | 8.81±0.40(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | 3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester Usage And Synthesis |
| Uses | Dovitinib RIBOTAC is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC can inhibit the metastasis of breast cancer and has anti-tumor activity[1]. | | in vivo | Dovitinib RIBOTAC (56 mg/kg; intraperitoneal injection; every other day; 30 days) exhibits anti-tumor activity in a xenograft mouse model of breast cancer[1].
Dovitinib RIBOTAC (56 mg/kg; intraperitoneal injection; every other day; 42 days) has an ameliorative effect in a mouse model of Alport Syndrome. It can stabilize the urine albumin concentration, reduce the levels of mature and precursor miR-21 in the kidneys, and increase the PPARα protein level[1]. | Animal Model: | MDA-MB-231-Luc cells treated female NOD/SCID mice[1] | | Dosage: | 56 mg/kg | | Administration: | Intraperitoneal injection; every other day; 30 days | | Result: | Inhibited breast cancer metastasis.
Decreased the number of lung nodules.
Significantly diminished miR-21 and pre-miR-21 expression.
Derepressed PDCD4 expression while having no effect on ERK or pERK levels.
|
| | References | [1] Zhang P, et al. Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment. J Am Chem Soc. 2021 Aug 25;143(33):13044-13055. DOI:10.1021/jacs.1c02248 |
| | 3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester Preparation Products And Raw materials |
|
|
Tag:3-Thiophenecarboxylic acid, 5-[[4-[[16-[4-[2-(4-amino-5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1H-benzimidazol-6-yl]-1-piperazinyl]-13-oxo-3,6,9-trioxa-12,14-diazahexadec-1-yl]oxy]-3-hydroxyphenyl]methylene]-4,5-dihydro-4-oxo-2-(phenylamino)-, ethyl ester(2759351-68-1)
Related Product Information
|